Why the billionaire Singh brothers could be entering endgame phase

Combined m-cap of companies promoted by Singh brothers down to Rs 83 bn from Rs 206 bn on eve of Ranbaxy sale

Two meetings of the boards of directors this week, of Fortis Healthcare and Religare Enterprises, will be in the spotlight, given their promoters’ recent brush with legal and regulatory issues.

For the billionaire Singh brothers, Malvinder and Shivinder, former promoters of pharmaceutical major Ranbaxy Laboratories with substantial stakes in Fortis Healthcare and Religare, the legal woes are far from over. 

Industry analysts and legal experts say this could mark the beginning of the endgame of the Ranbaxy saga, which began in 2008 when the promoters sold the family’s crown jewel to Japanese drug major Daiichi Sankyo.